Why Did That Drug Price Increase 6,000%? It’s The Law image

Forbes, February 10, 2017
Matthew Herper, quoting Rachel E. Sachs (Academic Fellow Alumna)


Read the full article

From the article:

Marathon is a member of the Pharmaceutical Research and Manufacturers of America (PhRMA), the drug industry trade group. Drug companies cannot use their usual argument of saying this is an “outlier.” This is one of their own – although Marathon may find itself feeling as if it is being ostracized from the club. As patent lawyer Rachel Sachs notes, the big drug giants need to distance themselves from this move – and maybe find a way to actually come to the table on preventing big drug price increases.


Read more here!

bioethics fda health care finance health law policy pharmaceuticals rachel sachs regulation